1	Evaluating the relationship between glycemic control and bone fragility within the UK
2	biobank: Observational and one-sample Mendelian randomization analyses
3	
4	Samuel Ghatan <sup>1</sup> , Fjorda Koromani <sup>1</sup> , Katerina Trajanoska <sup>2</sup> , Evert F.S. van Velsen <sup>1</sup> , Maryam
5	Kavousi <sup>3</sup> , M Carola. Zillikens, Carolina Medina-Gomez <sup>1</sup> , Ling Oei <sup>1*</sup> , Fernando
6	Rivadeneira <sup>1*,**</sup> .
7	
8	1. Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The
9	Netherlands
10	2. Canada Excellence Research Chair in Genomic Medicine, Victor Philip Dahdaleh
11	Institute of Genomic Medicine, Department of Human Genetics, Faculty of Medicine
12	and Health Sciences, McGill University, Montreal, QC, Canada.
13	3. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
14	
15	*Equal contribution
16	**Correspondence:
17	Fernando Rivadeneira, Department of Internal Medicine, Erasmus MC University Medical
18	Center Rotterdam, The Netherlands
19	Email: f.rivadeneira@erasmusmc.nl
20	
21	E-mail of other authors:
22	Samuel Ghatan (s.ghatan@erasmusmc.nl), Fjorda Koromani (f.koromani@erasmusmc.nl),
23	Katerina Trajanoska (katerina.trajanoska@mail.mcgill.ca), Evert F.S. van Velsen
24	(e.vanvelsen@erasmusmc.nl), Maryam Kavousi (m.kavousi@erasmusmc.nl), M. Carola
25	Zillikens (m.c.zillikens@erasmusmc.nl). Carolina, Medina-Gomez

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 (<u>m.medinagomez@erasmusmc.nl</u>), Ling Oei (loei@jvg.nl), Fernando Rivadeneira

- 27 (f.rivadeneira@erasmusmc.nl)
- 28
- 29 Abstract

Aims/hypothesis: This study aimed to: (1) examine the relationship between glycemic control, bone mineral density estimated from heel ultrasound (eBMD) and fracture risk in individuals with type 1 and type 2 diabetes and (2) perform a one-sample Mendelian randomization study to explore potential linear and non-linear associations between glycemic control, eBMD, and fractures.

35 Methods: This study comprised 452,131 individuals from the UK Biobank with glycated hemoglobin A1C (HbA1c) and eBMD levels. At baseline, 4,078 participants were diagnosed 36 with type 1 diabetes and 23,682 with type 2 diabetes. HbA1c was used to classify patients into 37 38 "adequately-" (ACD; n=17,078; HbA<sub>1c</sub> < 7.0%/53mmol/mol) and "inadequately-" (ICD; n=10,682; HbA<sub>1c</sub>  $\geq$  7.0%/53mmol/mol) controlled diabetes. The association between glycemic 39 40 control (continuous and categorical) and eBMD was tested using linear regression, while 41 fracture risk was estimated in Cox regression models, both controlling for covariates. 42 Mendelian randomization (MR) was used to evaluate linear and non-linear causal relationships 43 between HbA<sub>1c</sub> levels, fracture risk, and eBMD.

Results: In individuals with type 1 diabetes, a 1% unit (11mmol/mol) increase in HbA<sub>1c</sub> levels
was associated with a 12% increase in fracture risk (HR: 1.12, 95% CI [1.05-1.19]). Individuals
with type 1 diabetes had lower eBMD in both the ICD (beta = -0.08, 95% CI [-0.11, -0.04])
and ACD (beta = -0.05, 95% CI [-0.11,0.01]) groups, as compared to subjects without diabetes.
Fracture risk was highest in individuals with type 1 diabetes and ICD (HR 2.84, 95% CI [2.53, 3.19]), followed by those with ACD (HR 2.26, 95% CI [1.91, 2.69]). Individuals with type 2

50 diabetes had higher eBMD in both ICD (beta=0.12SD, 95%CI [0.10, 0.14]) and ACD 51 (beta=0.07SD, 95%CI [0.05, 0.08]) groups. Significant evidence for a non-linear association between HbA<sub>1c</sub> and fracture risk was observed (F-test ANOVA p-value = 0.002) in individuals 52 53 with type 2 diabetes, with risk being increased at both low and high levels of  $HbA_{1c}$ . Fracture 54 risk between the type 2 diabetes ACD and ICD groups was not significantly different (HR: 55 0.97, 95% CI [0.91-1.16]), despite increased BMD. In MR analyses genetically predicted higher 56 HbA<sub>1c</sub> levels were not significantly associated with fracture risk (Causal Risk Ratio: 1.04, 57 95%CI [0.95-1.14]). However, disease stratified analyses were underpowered. We did observe 58 evidence of a non-linear causal association with eBMD (quadratic test P-value = 0.0002), 59 indicating U-shaped relationship between HbA<sub>1c</sub> and eBMD.

60 Conclusion/interpretation: We obtained evidence that lower HbA<sub>1c</sub> levels will reduce fracture 61 risk in patients with type 1 diabetes. In individuals with type 2 diabetes, lowering HbA<sub>1c</sub> levels 62 can mitigate the risk of fractures up to a threshold, beyond which the risk may begin to rise 63 once more. MR analyses demonstrated a causal relationship between genetically predicted 64 HbA<sub>1c</sub> levels and eBMD, but not fracture risk.

- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73

## 74 Introduction

75 Diabetes mellitus is a common metabolic disorder characterized by elevated blood glucose 76 levels, affecting millions of individuals worldwide. While the detrimental effects of poor 77 glycemic control in diabetes on various organ systems have been extensively investigated [1], its impact on skeletal health remains an area of ongoing research. Previous studies have 78 79 established fracture risk as a complication of diabetes [2-4]. Fractures pose significant 80 challenges, leading to considerable morbidity, mortality, and healthcare costs [5, 6]. However, 81 understanding the complex relation between glycemic control, measured by glycated 82 hemoglobin (HbA<sub>1c</sub>) levels, and fracture risk in individuals with both type 1 diabetes and type 83 2 diabetes is crucial for implementing preventive measures and improving patient outcomes 84 [7]. Additionally, investigating the relationship between glycemic control and bone mineral 85 density (BMD), a key determinant of fracture susceptibility, can offer insights into potential 86 therapeutic strategies for mitigating the skeletal complications associated with diabetes. 87 Glycemic control has been shown to be a key determinant of other complications of diabetes 88 including microvascular disease, myocardial infarction and all-cause mortality [1]. To address 89 these knowledge gaps comprehensively, we conducted a large-scale observational study 90 utilizing data from the UK Biobank, a well-characterized population-based resource [8]. Our 91 study aimed to examine the relationship between glycemic control, BMD and fracture risk in 92 individuals with type 1 diabetes and type 2 diabetes; and utilize linear and non-linear 93 Mendelian randomization to explore potential causal associations.

94

95 **Research Design and Methods** 

96 Study population

97 The UK biobank is a prospective cohort study that recruited up to 502,410 participants across

98 22 centers in the UK. Participants were aged between 40-59 years at baseline [8]. HbA<sub>1c</sub>

99 levels were measured in 482,253 individuals across two center visits. The initial assessment 100 visit took place between 2006-2010 and encompassed 95% of the measurements taken. The 101 second assessment visit took place between 2012-2013. The date of HbA<sub>1c</sub> measurement was 102 established as baseline. Individuals with prevalent fractures at baseline were excluded 103 (fracture definition provided below). The median follow-up time was 11.72 years during 104 which 20,414 incident fractures occurred. The follow-up time end date was determined as the 105 date of the last recorded fracture. Individuals who did not fracture or died before the end date 106 were censored. The date of an individual's death was obtained via death registry (data field 107 40000). A subset of 452,131 individuals also had eBMD measurements available, obtained 108 over three center visits. The initial visit took place between 2006-2010 encompassing 90% of 109 the measurements taken. Subsequent visits took place between 2012-2014 and 2014-2016. 110 The Mendelian randomization study was performed on a subset of 379,600 individuals of 111 European ancestry who had genotype information available [9]. The UK biobank was 112 conducted in full accordance with the ethical principles outlined in the Declaration of 113 Helsinki, as revised in 2013, including adherence to protocols approved by their respective 114 institutional ethics review committees and all participants provided written informed consent. 115 Diabetes definition and glycemic measures 116 Individuals with type 2 diabetes were identified either via self-reporting at baseline (data field

117 130709), obtaining a HbA<sub>1c</sub> level > 6.5% (48 mmol/mol) at baseline, or via a recorded 118 International Classification of Diseases, Tenth Revision (ICD-10) code E11 (non-insulin-119 dependent diabetes mellitus) (data field 130708). Similarly, individuals with type 1 diabetes 120 were defined using self-reported data, as well as, the ICD-10 code E10 (Insulin-dependent 121 diabetes mellitus). Plasma HbA<sub>1c</sub> levels were measured using variant II turbo Hemoglobin 122 Testing System; from Bio-Rad. Individuals with diabetes and HbA<sub>1c</sub> levels  $\geq$  7% 123 (53mmol/mol) were considered to have inadequate glycemic control, conversely those with

<7% were considered as having adequate control, according to American Diabetes Association</li>
(ADA) guidelines [10]. The duration of diabetes was determined based on either the selfreported age of diabetes diagnosis (data field 2976) or the earliest date of the corresponding
ICD-10 code. In cases where self-reported ages were unavailable or entered incorrectly, they
were replaced with the first date of the ICD-10 code. Pre-diabetes was defined using ADA
guidelines as HbA<sub>1c</sub> levels of 5.7-6.4% (39-46mmol/mol) [11].

130

131 Fractures and BMD measurements

132 Estimated BMD (eBMD) measurements were calculated from measured quantitative 133 ultrasound speed of sound (SOS) and broadband ultrasound attenuation (BUA) of the heel. 134 Measurements were collected over three timepoints. The data collection and quality control of 135 eBMD measurements were conducted in accordance with the procedure outlined by the 136 GEFOS consortium [12]. Fractures were defined according to ICD-10 codes. A full list of the 137 codes used can be located in supplementary table 1. Fractures of the skull, face, hands and feet, 138 atypical femoral fractures, pathological fractures due to malignancy, periprosthetic, and healed 139 fracture codes were excluded. Individuals who retracted their informed consent, as of May 4<sup>th</sup>, 140 2023, were removed.

141

142 Complications

143 Cardiovascular disease was defined using the ICD-10 codes I20, angina pectoris; I21, acute 144 myocardial infarction; 122 subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) 145 myocardial infarction; I23, certain current complications following ST elevation (STEMI) and 146 non-ST elevation (NSTEMI) myocardial infarction; I24, other acute ischemic heart diseases; 147 or I25, chronic ischemic heart disease. Chronic kidney disease was defined by ICD-10 code 148 N18; Chronic kidney disease. Diabetic retinopathy was defined by the ICD-10 codes: E08.3 -

Diabetes mellitus due to underlying condition with ophthalmic complications, E09.3 - Drug or
chemical induced diabetes mellitus with ophthalmic complications, E10.3 - Type 1 diabetes
mellitus with ophthalmic complications, E11.3 - Type 2 diabetes mellitus with ophthalmic
complications, E13.3 - Other specified diabetes mellitus with ophthalmic complications.

- -

154 Statistical analyses

155 Observational associations

The reporting of epidemiological results was undertaken following the STROBE and 156 157 STROBE-MR guidelines. The effect of HbA<sub>1C</sub> on BMD and fracture risk was estimated from 158 linear regression and Cox proportional hazards models, respectively. Estimates were also 159 obtained for the association between glycemic groups (i.e., ACD, ICD, pre-diabetes) and 160 outcomes in comparison to diabetes-free individuals. Additionally, to compare the fracture risk 161 between glycemic groups hazard ratios (HR) were obtained when setting ACD as the reference group. The continuous effect of HbA<sub>1c</sub> levels on eBMD and fractures was assessed in type 1 162 163 diabetes, type 2 diabetes and diabetes-free sub-group analyses. Non-linear effects were also 164 evaluated using linear tail-restricted cubic spline models with 3 knots using the 'rms' package 165 in R. The number of knots was determined by visual inspection of plots and using Akaike information criterion, to compare models with different degrees of freedom. The significance 166 167 of the non-linear spline terms was evaluated using an F-test ANOVA test. All models were 168 adjusted for: age, age<sup>2</sup>, sex, height, weight, smoking status (data field 20116), alcohol intake 169 (data field 1558), creatinine (23478), c-reactive protein (data field 30710), menopause (data 170 field 2724), genetic ethnicity (data field 22006), self-reported ethnicity (data field 21000), 171 index of Multiple Deprivation (data field 26410), and duration of moderate activity (data field 172 894). In Cox models the proportionality of hazards assumption was evaluated using Schoenfeld

residual plots. Variables with missing information (less than 20%) were imputed using the micepackage in R [13].

175

176 Sensitivity analyses

For sensitivity analyses, a second higher HbA<sub>1c</sub> cut-off was defined at 9% (75mmol/mol) with 177 178 those above it being classified as having adequate control and vice versa. This cut-off was 179 motivated by papers showing increased fracture risk at higher HbA<sub>1c</sub> cut-offs [14, 15]. Additionally, to investigate the association between low HbA<sub>1c</sub> and fracture risk, we further 180 181 split those individuals with type 2 diabetes and ACD by a HbA<sub>1c</sub> level of below 5.4% 182 (36mmol/mol) (the mean of the sample) and labelled these individuals as hypoglycemic. The risk of fractures in individuals with pre-diabetes was also evaluated. The effect of diabetes 183 184 duration of fracture risk was also assessed in individuals with type 2 diabetes and available 185 duration data (n=19,263) by including diabetes duration as a covariate in the Cox model. 186 Additionally, disease duration was categorized into 3 groups: less than 5 years, more than 5 187 years less but than 10 years, and 10 years and greater. Effect estimates were obtained using 188 Cox regression models with the group of less than 5 years as the reference category. Lastly, to 189 assess the potential effect diabetic complications and comorbidities on fracture risk and HbA1c 190 levels we adjusted our statistical models for hemoglobin concentration (data field 30020), as a 191 measure of anemia, chronic kidney disease, cardiovascular disease, and diabetic retinopathy.

192

193 Selection of genetic instrumental variables

We selected 88 conditionally independent genetic variants as instrumental variables for HbA<sub>1c</sub> levels (supplementary table 2) based on their association with HbA<sub>1c</sub> ( $p<5x10^{-8}$ ) in a genomewide association study of 191,362 individuals of European ancestry [16]. Palindromic SNPs were removed and replaced by linkage disequilibrium proxies ( $r^2 > 0.80$ ). Standardized genetic

risk scores (GRS) were constructed using the 88 genetic variants for individuals with available genetic data. To test the instrument strength, linear regression models, adjusted for age at baseline, sex, and 10 genetic principal components of ancestry, were constructed. The GRS explained 3% of the variance of HbA<sub>1c</sub> within the UK biobank population and displayed an F statistic of 1068.

203

## 204 Linear Mendelian randomization

205 For a genetic variant to act as a valid instrumental variable in a MR analysis it had to satisfy 206 the following assumptions: 1) relevance: reliably associated with each of the exposures 207 included in the model; 2) exclusion restriction: the variant needs to be associated with the 208 outcome only through the exposure of interest; and 3) independence: the variant should be 209 conditionally independent of the outcome given the exposure and confounding factors [17]. To 210 obtain linear causal inferences, we applied a two-stage least squares regression (2SLS) for 211 continuous outcomes and structural mean models (SMM) for binary outcomes [18, 19]. Both 212 regression stages were adjusted by age, sex, and the first 10 principal components of genetic 213 ancestry. A sensitivity analysis was performed by removing related individuals (kingship 214 coefficient < 0.0884) and recalculating regression estimates [20]. MR power calculations were 215 derived using the mRnd web tool [21].

216

## 217 Non-linear Mendelian randomization

To assess non-linear causal effects we sought to stratify individuals and calculate localized average causal effects (LACE) using the ratio method (instrumental variable outcome association divided by the instrumental variable exposure association) [22]. To stratify individuals we adopted the doubly-ranked method [22], which overcomes an important limitation of the residual method, namely that it assumes that the effect of the genetic

223 instrument on the exposure is constant and linear. Briefly, the doubly-ranked method is a non-224 parametric approach for exposure stratification, such that, the stratification is not a function of 225 the instrumental variables and each strata has a different average level of the exposure. This 226 involves the initial ranking of individuals based on their level of the instrumental variables, which are then divided into pre-strata. After this, the individuals within each pre-stratum are 227 228 ranked based on their level of exposure and further divided into strata. Additional test statistics 229 for non-linearity were calculated using the 'SUMnlmr' R package [23]. Next, we obtained 230 causal inferences on the shape of the exposure-outcome relationship using fractional 231 polynomials [24]. These polynomials represent the stratification of individuals into either 10 232 strata or 100 strata. Non-linearity tests included: the fractional polynomial degree test, the 233 fractional polynomial non-linearity test, the quadratic test and Cochran's Q-test. The fractional polynomial degree test was used to indicate the polynomial degree preference, with a low p-234 235 value indicating preference of a degree 2 polynomial. The fractional polynomial non-linearity 236 tests the best-fitting fractional polynomial of a degree 1 against the linear model, with a low p-237 value indicating a preference of fractional polynomials of degree 1. The quadratic test meta 238 regresses LACE estimates against the mean value of the exposure in each stratum, with a lower 239 p-value indicating non-linearity. Lastly, the Cochran's Q-test, tests also whether the LACE estimates differ more than expected by chance, with a lower p-value indicating non-linearity 240 241 [23, 24].

242

243 Results

244 Population characteristics

This study comprised 452,131 individuals from the UK biobank cohort study. At baseline, 4,078 (0.9%) individuals had type 1 diabetes and 23,682 (5.2%) had type 2 diabetes. A third group was comprised of individuals without diabetes (n = 424,371) with a median glycated

248	hemoglobin levels (HbA <sub>1c</sub> ) level of 5.4%. A median of HbA <sub>1c</sub> level of 7.4% was observed in
249	individuals with type 1 diabetes and of 6.6% in those with type 2 diabetes. Individuals with
250	each type of diabetes were stratified into two groups: $HbA_{1c} \ge 7.0\%/53mmol/mol$ defined as
251	Inadequately Controlled Diabetes (ICD; n=10,682); representing 62.9% of those with type 1
252	diabetes (n = 2,565) and 34.3% of those with type 2 diabetes (n = 8,117); and those with HbA <sub>1c</sub>
253	<7.0%/53mmol/mol, defined as Adequately Controlled Diabetes (ACD; n =17,078). The
254	median follow-up time was 11.7 years period during which 20,414 incident fractures occurred.
255	The mean age of the participants was 58 years old $(SD = 8)$ with similar proportion of men and
256	women (Table 1). In individuals with type 2 diabetes the mean disease duration was 5.5 years
257	(SD = 5.2) before inclusion at baseline. Estimated bone mineral density (eBMD), derived via
258	heel ultrasound, was measured in all individuals.

260 Table 1 – Participant baseline characteristics.

	Women	Men
Ν	247,712	204,419
Age (years)	58 (50-63)	58 (50-64)
Height (cm)	162 (158-167)	176 (171-180)
Weight (kg)	69 (61.6-78.4)	84 (76-93)
eBMD (g/cm <sup>2</sup> )	0.51 (0.43-0.59)	0.56 (0.48-0.64)
HbA1c (%)	5.4 (5.2-5.6)	5.4 (5.2-5.6)
type 2 diabetes, n(%)	9,417 (3.8%)	14,265 (7.0%)
type 1 diabetes, n(%)	1,752 (0.7%)	2,326 (1.1%)
ACD (<7%/53mmol/mol), n(%)	7,057 (2.8%)	10,021(5.0%)
ICD ( <u>&gt;</u> 7%/53mmol/mol), n(%)	4,112 (1.7%)	6,570 (3.2%)
Incident fractures, n(%)	13,636 (5.5%)	6,778 (3.3%)

Moderate Activity (mins/day)	60 (30-66)	60 (30-66)	
Creatinine (umol/L)		63.6 (57.3-71.2)	79.3 (72.2-87.8)
CRP (mg/L)		1.47 (0.67-2.83)	1.34 (0.68-2.56)
Deprivation*		15.2 (8.16-20.67)	15.59 (8.27-21.35)
Menopause	Yes	150,586	0
	No	58,105	0
	Not sure (had a		
	hysterectomy)	28,215	0
	Not sure (other		
	reason)	10,565	0
Smoking	Current	22,129	25,368
	Previous	78,245	78,755
	Never	147,338	100,296
Alcohol intake	Daily	40,165	52,273
	3-4 times a week	51,272	53,968
	1-2 a week	64,199	53,036
	1-3 a month	32,311	18,063
	Occasionally	36,740	14,595
	Never	23,025	12,484

261

262 Values depict medians and interquartile-ranges. ICD = inadequately controlled diabetes, ACD = adequately controlled diabetes, CRP = C-reactive protein. \* Deprivation refers to the English 263 264 indices of deprivation. A composite measure of social economic status.

265

267 Glycemic control and estimated Bone Mineral Density

268 In individuals with type 1 diabetes, HbA<sub>1c</sub> levels were not significantly associated with eBMD 269 (beta=0.01SD, 95%CI [-0.03, 0.02]) (supplementary table 5), although there was weak 270 evidence suggesting a non-linear U-shaped relationship (F-test ANOVA p-value = 0.08) 271 (Figure 1a). In type 1 diabetes, the ACD (beta=-0.04 SD, 95% CI [-0.08, 0.01]) and ICD (beta=-272 0.07 SD, 95%CI [-0.10, -0.02]) groups displayed lower eBMD with respect to HbA<sub>1c</sub> levels, in 273 comparison to diabetes-free individuals (Figure 2a). In individuals with type 2 diabetes, a 1% 274 (11mmol/mol) increase in HbA1c levels was associated with a 0.01 SD eBMD increase (95% CI 275 [0.00-0.03]) (supplementary table 5). No evidence of a non-linear association between HbA<sub>1c</sub> 276 and eBMD was observed for type 2 diabetes in sub-group analyses (F-test ANOVA p-value = 277 0.72) (Figure 1b). In the type 2 diabetes analysis, stratification by glycemic control yielded 278 concordant results with a positive association between HbA1c and eBMD in the ACD 279 (beta=0.07SD, 95%CI [0.05, 0.08]) and ICD (beta=0.12SD, 95%CI [0.10, 0.14]) groups. 280 Individuals with ICD had increased eBMD in comparison to those with ACD (beta=0.04, 281 95%CI [0.01, 0.06]). In diabetes-free individuals, HbA<sub>1c</sub> levels were negatively associated to 282 eBMD (beta=-0.05SD, 95%CI [-0.06, -0.04]). In addition, evidence for a non-linear association 283 between HbA<sub>1c</sub> and eBMD was also observed (F-test ANOVA p-value = 0.02) (Figure 1c).

284

285 Glycemic control and fracture risk

A 1% (11mmol/mol) increase in HbA<sub>1c</sub> levels was associated with a 12% increase in fracture risk (HR: 1.12, 95%CI [1.05-1.19]) in individuals with type 1 diabetes (Figure 1d, supplementary table 3). Risk estimates were similar between men and women (supplementary table 4). In the type 1 diabetes sub-group analysis Cox regression Schoenfeld residual plots indicated a violation of the proportionality of hazards assumption for age as a covariate. However, upon conducting analyses stratified by age, with groups delineated as <38-50, <5055, <55-60, <60-65, and <65-81 years, we found that the hazard ratios adhered to the</li>
proportionality assumption (supplementary Figure 1). Subsequently, associations between
glycemic control groups and fracture risk were evaluated. As compared to individuals without
diabetes, those with type 1 diabetes had increased fracture risk in both the ACD (HR 2.26,
95%CI [1.91, 2.69]) and ICD (HR 2.84, 95%CI [2.53, 3.19]) groups (Figure 2b). Further,
individuals with ICD had a higher fracture risk than those with ACD (1.27, 95%CI [1.04,
1.57]).

299 Fracture risk in individuals with type 2 diabetes showed evidence for a U-shaped non-linear 300 association with increased risk (F-test ANOVA p-value = 0.002) observed at both low and high 301 levels of HbA1C (Figure 2e). A similar non-linear association was observed in diabetes-free 302 individuals (F-test ANOVA p-value < 0.001), although attenuated within healthy HbA<sub>1c</sub> levels (Figure 2f). Duration of diabetes was found to be associated to fracture risk (supplementary 303 304 Figure 2). However, when included in the type 2 diabetes Cox model no modification of the 305 effect of HbA<sub>1c</sub> on fracture risk was observed. Fracture risk was increased in type 2 diabetes 306 ACD (1.19, 95% CI [1.11, 1.28]) and ICD (1.23, 95% CI [1.11, 1.36]) groups, in comparison to 307 diabetes-free individuals (Figure 2b). However, individuals with ICD did not have an increased 308 fracture risk in comparison to those with ACD (0.97, 95%CI [0.91, 1.16]). Dichotomizing on 309 a HbA<sub>1c</sub> level of 9% produced similar observations (supplementary Figure 3, supplementary 310 table 3). We further split individuals with type 2 diabetes and ACD with a HbA<sub>1c</sub> level of lower 311 than 5.4% and labelled this group as hypoglycemic (n=1,401). Individuals within the 312 hypoglycemic group had the greatest fracture risk (1.49, 95% CI [1.20, 1.86]) (supplementary 313 Figure 4). Additionally, individuals with pre-diabetes did not present higher fracture risk (HR: 314 0.99, 95%CI [0.96-1.03]; n=61,951) in comparison to controls.







319 Reference value was set to 5.4% (36mmol/mol) for all analysis groups. The shaded area

320 represents the 95% confidence interval. For eBMD plots the covariates were set to the mean

321 values. For example, for type 2 diabetes the covariates were: age=61, sex = male,

322 weight=87.9 height=169, alcohol intake=1-2 per week. Creatinine=72.18 CRP=2.1,

323 deprivation score=17.42, ethnicity = white European, duration of moderate activity=60, Non-

- 324 smoker.
- 325
- 326



327

328 Figure 2 - a) Forest plot depicting associations between eBMD and glycemic control groups 329 in comparison to controls. b) Forest plot depicting fracture risk ratios of glycemic control groups in comparison to controls. ICD = inadequately controlled diabetes, ACD = adequately 330 331 controlled diabetes.



334 One-sample Mendelian randomization analyses revealed no significant evidence of a linear or 335 a non-linear association between genetically predicted HbA<sub>1c</sub> levels and fracture risk (power = 336 0.94) (supplementary Figure 5, supplementary table 6 & 7). With regards to eBMD, we 337 observed significant evidence of a negative linear association between genetically predicted 338 HbA<sub>1c</sub> levels and eBMD, in diabetes-free (beta=-0.09, 95%CI [-0.12, -0.05]) individuals and 339 in the total population (beta=-0.08, 95%CI [-0.11, -0.05]) (supplementary Figure 6a, 340 supplementary table 8). We observed no significant difference in effect estimates when related 341 individuals were removed (supplementary table 8). Non-linear Mendelian randomization 342 revealed strong non-linear relationship between HbA<sub>1c</sub> and eBMD in the overall population. 343 The quadratic test yielded a p-value of 0.0002. This was supported by evidence from the 344 fractional polynomial test (p-value = 0.009). Additional, evidence suggested that best-fitting 345 fractional polynomial of degree 2 fitted the data better than the best-fitting fractional 346 polynomial of degree 1 (p-value = 0.02). The best-fitting fractional polynomial of degree 2 had 347 powers 1 and -1. The Cochran Q test was also significant (p-value = 0.001). Graphs and strata 348 estimates indicated a negative slope from HbA<sub>1c</sub> levels between 4 - 6.5%, after which the slope 349 becomes positive (supplementary Figure 6b, supplementary table 9, 10, 11). This relationship 350 was not evident in analyses stratified by disease status (supplementary table 9). Yet, these 351 analyses were underpowered (see supplementary tables 6 & 8 for power calculations).

352

353 Discussion

We confirm an increased fracture risk in individuals with type 1 and type 2 diabetes from a relatively healthy young cohort [25]. Further, we observed a linear association between HbA<sub>1c</sub> and an increased fracture risk in individuals with type 1 diabetes and a non-linear association in individuals with type 2 diabetes. Individuals with type 1 diabetes and inadequately controlled diabetes (ICD, >7%/53mmol/mol) had greater fracture risk, than those with adequately

359 controlled diabetes (ACD, < 7%/53mmol/mol). In type 2 diabetes, fracture risk did not differ 360 between ACD and ICD groups even after increasing the HbA<sub>1c</sub> dichotomization cut-off to 9% 361 (75mmol/mol). This lack of difference in fracture risk was observed despite higher BMD levels 362 in individuals with ICD. However, individuals with type 2 diabetes and a HbA<sub>1c</sub> level below 5.4% (36mmol/mol) had the greatest fracture risk. In type 1 diabetes, we observed evidence 363 364 that lowering HbA<sub>1c</sub> levels will reduce fracture risk. In type 2 diabetes, we observed evidence 365 that both higher and lower HbA<sub>1c</sub> levels were associated with increased fracture risk. Our work brings to perspective the results of some previous studies [15, 26-29] indicating that individuals 366 367 with type 2 diabetes and ACD present lower or similar fracture risk to that of diabetes-free 368 individuals. Leveraging genetic information, we observed no association between genetically predicted higher HbA1c levels and fracture risk. However, we did observe evidence of a non-369 370 linear association between genetically-predicted HbA1c levels and eBMD in the total 371 population. We observed a negative association between HbA<sub>1c</sub> and eBMD between 4.0 - 6.5% 372 (20-48mmol/mol), after which the association to eBMD became positive. These results are 373 concordant with our findings in the observational analysis and provide evidence of a causal 374 non-linear relationship.

375 Previous studies have suggested that the increased fracture risk in type 2 diabetes is largely 376 mediated by poor glycemic control [15, 26-29]. While individuals with type 2 diabetes and 377 ICD showed a higher fracture risk compared to those without diabetes, the ACD group also 378 had an increased fracture risk. No difference between ICD and ACD groups regarding fracture 379 risk was observed, even after increasing the cut-off to 9% (75mmol/mol). Paradoxically, ICD 380 was associated with higher eBMD, but this did not beget an expected decrease in fracture risk, 381 a well-established phenomenon observed in individuals with type 2 diabetes [2]. Many of the 382 studies reporting a significant relationship between poor glycemic control and fracture risk 383 report varying cut-offs of HbA<sub>1c</sub> levels for defining adequate/inadequate glycemic control.

384 Clinicians often utilize cut-offs or threshold values to assist in the process of making decisions. 385 However, their effectiveness is a subject of debate [30]. Cut-offs are problematic because they 386 typically correspond to the specific population being studied and thus seldom produce 387 consistent outcomes when applied to separate studies or datasets. Additionally, employing cut-388 offs to categorize a continuous predictor can potentially hinder accurate risk prediction [31]. 389 Our results describe a U-shaped relationship between HbA<sub>1c</sub> and fracture risk in individuals 390 with type 2 diabetes and diabetes-free individuals. Similarly, a large retrospective study of 391 652,901 elderly male veterans with type 2 diabetes observed that fracture risk was not increased 392 in individuals with  $HbA_{1c} > 8.5\%$  (69mmol/mol), but was increased in individuals with  $HbA_{1c}$ 393 < 6.5% (48mmol/mol) [32]. Individuals with low levels of HbA<sub>1c</sub> can be considered as 394 hypoglycemic [33]. Evidence suggests that hypoglycemia can lead to a loss of balance and an 395 increase in falls, which can subsequently increase their fracture risk [34]. While this 396 explanation seems plausible, it is important to state that the ADA suggests that HbA<sub>1c</sub> "does 397 not provide a measure of glycemic variability or hypoglycemia" [31]. Alternatively, the 398 observed association with increased fracture risk in individuals with very low HbA1c levels 399 could be confounded by the use of glucose-lowering medication. However, this would not 400 explain the increased risk in diabetes-free individuals. Individuals with anemia or other 401 conditions shortening the lifespan of red blood cells (i.e., glucose-6-phosphate dehydrogenase 402 deficiency, sickle-cell disease, etc.), may have underestimated HbA<sub>1c</sub> levels [35]. Considering 403 the association between anemia and heightened risk of fractures [36], we incorporated 404 measured hemoglobin concentrations into our statistical models to evaluate their impact. The 405 inclusion of hemoglobin markedly enhanced the model's explanatory power, as evidenced by 406 a significant F-test ANOVA (p-value  $< 2x10^{-16}$ ). Nevertheless, the estimated effects were 407 not statistically different from those in the model that excluded hemoglobin concentrations 408 (supplementary table 12). In type 1 diabetes, poor glycemic control was linearly associated

409 with increased fracture risk. No significant differences in eBMD were observed across 410 glycemic control groups. This could be a consequence of non-linear effects (for which we 411 observed weak evidence) and/or low statistical power. In line with our findings, a nested case-412 control study in the UK reported no differences in fracture risk in relation to glycemic control 413 among individuals with type 2 diabetes. However, similar to our study, they did observe a 414 difference in fracture risk for those with type 1 diabetes [37]. Other studies also report increased 415 fracture risk in type 1 diabetes individuals with poor glycemic control [14, 38]. Nevertheless, 416 these studies reported different magnitude of effects likely due to differences in underlying 417 cohort populations. Differences in the relationship between HbA<sub>1c</sub> and bone fragility across the 418 different types of diabetes are expected. This can be a consequence of the distinct pathological 419 mechanisms, age of disease onset and duration [39, 40]. Diabetes disease duration has been shown to affect both fracture risk and glycemic control in type 1 diabetes and type 2 diabetes 420 421 [14]. However, when including duration as a covariate in our analysis, we observed no 422 modification of the association between HbA<sub>1c</sub> and fracture risk.

423 Our study has some limitations proper to observational studies. Despite the large sample size, 424 the low prevalence of incident fractures in this population means statistical power is still limited 425 for the one-sample Mendelian randomization analyses of fracture risk. Power calculations for 426 diabetes-specific stratified Mendelian randomization analyses suggest that a sample size of 427 218,351 individuals with diabetes is needed to achieve 80% power. We were unable to account 428 fully for the consequences of diabetes disease duration and inadequate control in this study. 429 Yet, controlling for diverse diabetes complications like diabetic retinopathy, kidney disease, 430 and microvascular disease showed consistent effect estimates (supplementary table 12). 431 Further, we employed  $HbA_{1c}$  which was only measured at baseline and therefore was not 432 reflective of long-term glycemic control. Additionally, the UK Biobank has been reported to 433 suffer from 'healthy volunteer bias' [25]. As such, longitudinal studies with repeated

measurements of HbA<sub>1c</sub>, a detailed assessment of diabetes duration, and evaluation of DXAderived BMD change over time will provide a more comprehensive understanding of these
associations. Additionally, prospective studies should consider examining other factors such as
glycemic variability, hypoglycemic events, and the effects of glucose-lowering medications on
fracture risk.

439 We observed distinct relationships between HbA<sub>1c</sub> and bone fragility in type 1 diabetes and 440 type 2 diabetes and postulate that this is due to the underlying differences in disease pathology, 441 including the anabolic effect of insulin on bone. We advise against the use of hard cut-offs for 442 defining adequate/inadequate glycemic control as these can vary across the populations being studied. We obtained evidence that lower HbA<sub>1c</sub> levels will reduce fracture risk in patients with 443 444 type 1 diabetes. In individuals with type 2 diabetes, lowering HbA<sub>1c</sub> levels can mitigate the risk 445 of fractures up to a threshold, beyond which the risk may begin to rise once more. Our study 446 contributes to the growing body of evidence on the relationship between glycemic control, fractures, and bone health, highlighting the need for individualized management strategies in 447 448 individuals with diabetes to optimize skeletal outcomes and reduce fracture risk. Furthermore, longitudinal studies with repeated measurements are needed to identify the key determinants 449 450 of fracture risk in type 2 diabetes.

451

453 1. Holman, R.R., et al., 10-Year Follow-up of Intensive Glucose Control in Type 2 454 Diabetes. New England Journal of Medicine, 2008. 359(15): p. 1577-1589. 455 2. Hofbauer, L.C., et al., Bone fragility in diabetes: novel concepts and clinical 456 implications. The Lancet Diabetes & Endocrinology, 2022. 10(3): p. 207-220. 457 Vilaca, T., et al., The risk of hip and non-vertebral fractures in type 1 and type 2 3. 458 diabetes: A systematic review and meta-analysis update. Bone, 2020. 137: p. 115457. 459 4. Kvist, A.V., et al., Site-Specific Fracture Incidence Rates Among Patients With Type 460 1 Diabetes, Type 2 Diabetes, or Without Diabetes in Denmark (1997–2017). Diabetes 461 Care, 2023. 46(3): p. 633-642. 462 5. Johnell, O., The socioeconomic burden of fractures: Today and in the 21st century. The American Journal of Medicine, 1997. 103(2, Supplement 1): p. S20-S26. 463

<sup>452</sup> References

<ol> <li>Ferrari, S.L., et al., Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int, 2018. 29(12): p. 2583-2596.</li> <li>Sudlow, C., et al., UK biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Medicine, 2015. 12(3): p. e1001779.</li> <li>Bycroft, C., et al., The UK Biobank resource with deep phenotyping and genomic data. Nature, 2018. 562(7726): p. 203-209.</li> <li>Association, A.D., 6. Glycemic Targets. Diabetes Care, 2014. 38(Supplement_1): p. S33-S40.</li> <li>Association, A.D., 6. Glycemic Targets. Diabetes Care, 2014. 38(Supplement_1): p. S33-S40.</li> <li>American Diabetes, A., Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2013. 37(Supplement_1): p. S81-S90.</li> <li>Morris, J.A., et al., An atdas of genetic influences on osteoporosis in humans and mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>Zhang, Z., Multiple imputation with multivariate inputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations lycersion 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30</li></ol>	464 465	6.	Burge, R.T., et al., The cost of osteoporotic fractures in the UK: projections for 2000–2020. Journal of Medical Economics, 2001. 4(1-4): p. 51-62.
<ul> <li>467 emerging challenge. Osteoporos Int, 2018. 29(12): p. 2585-2596.</li> <li>8. Sudlow, C., et al., UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Medicine, 2015. 12(3): p. e1001779.</li> <li>9. Bycroft, C., et al., The UK Biobank resource with deep phenotyping and genomic data. Nature, 2018. 562(7726): p. 203-209.</li> <li>10. Association, A.D., 6. Glycemic Targets. Diabetes Care, 2014. 38(Supplement_1): p. S33-S40.</li> <li>11. American Diabetes, A., Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2013. 37(Supplement_1): p. S81-S90.</li> <li>12. Morris, J.A., et al., An atlas of genetic influences on osteoporosis in humans and mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>13. Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>14. Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>15. Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>16. Chen, J., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>18. Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>19. Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>20. Manichaiku, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>21. Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <l< td=""><td>466</td><td>7.</td><td>Ferrari, S.L., et al., Diagnosis and management of bone fragility in diabetes: an</td></l<></ul>	466	7.	Ferrari, S.L., et al., Diagnosis and management of bone fragility in diabetes: an
<ol> <li>Sudlow, C., et al., UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Medicine, 2015. 12(3): p. e1001779.</li> <li>Bycroft, C., et al., The UK Biobank resource with deep phenotyping and genomic data. Nature, 2018. 562(7726): p. 203-209.</li> <li>Association, A.D., 6. Glycemic Targets. Diabetes Care, 2014. 38(Supplement_1): p. S33-S40.</li> <li>American Diabetes, A., Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2013. 37(Supplement_1): p. S81-S90.</li> <li>American Diabetes, A., An atlas of genetic influences on osteoporosis in humans and mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Roust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhabazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodo</li></ol>	467		emerging challenge. Osteoporos Int, 2018. 29(12): p. 2585-2596.
<ul> <li>of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Medicine, 2015. 12(3): p. e1001779.</li> <li>Bycroft, C., et al., The UK Biobank resource with deep phenotyping and genomic data. Nature, 2018. 562(7726): p. 203-209.</li> <li>Association, A.D., 6. Glycemic Targets. Diabetes Care, 2014. 38(Supplement_1): p. S33-S40.</li> <li>American Diabetes, A., Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2013. 37(Supplement_1): p. S81-S90.</li> <li>Morris, J.A., et al., An atlas of genetic influences on osteoporosis in humans and mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019.</li> <li>L5: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. WellCome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations for studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K.Shakhabzov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.49730.</li> <li>Staley, J.R. and S. Burgess, Seniparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with appli</li></ul>	468	8.	Sudlow, C., et al., UK Biobank: An Open Access Resource for Identifying the Causes
<ol> <li>2015. 12(3): p. e1001779.</li> <li>Bycroft, C., et al., The UK Biobank resource with deep phenotyping and genomic data. Nature, 2018. 562(7726): p. 203-209.</li> <li>Association, A.D., 6. Glycemic Targets. Diabetes Care, 2014. 38(Supplement_1): p. S33-S40.</li> <li>American Diabetes, A., Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2013. 37(Supplement_1): p. S81-S90.</li> <li>Morris, J.A., et al., An atlas of genetic influences on osteoporosis in humans and mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations (version 2; peer review: 2 approved). Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakibazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28497930.</li> <li>Hadolong, T., et al., Relaxing parametric a</li></ol>	469		of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Medicine,
<ol> <li>Bycroft, C., et al., The UK Biobank resource with deep phenotyping and genomic data. Nature, 2018. 562(7726): p. 203-209.</li> <li>Association, A.D., 6. Glycemic Targets. Diabetes Care, 2014. 38(Supplement_1): p. S33-S40.</li> <li>American Diabetes, A., Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2013. 37(Supplement_1): p. S81-S90.</li> <li>Morris, J.A., et al., An atlas of genetic influences on osteoporosis in humans and mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2: peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomizat</li></ol>	470		2015. 12(3): p. e1001779.
<ul> <li>data. Nature, 2018. 562(7726): p. 203-209.</li> <li>Association, A.D., 6. Glycemic Targets. Diabetes Care, 2014. 38(Supplement_1): p. 833-840.</li> <li>American Diabetes, A., Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2013. 37(Supplement_1): p. 881-590.</li> <li>Morris, J.A., et al., An atlas of genetic influences on osteoporosis in humans and mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Conway, B.N., et al., Glycemic control and fracture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 20(2): p. 287-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization suitige. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization aning a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Pro</li></ul>	471	9.	Bycroft, C., et al., The UK Biobank resource with deep phenotyping and genomic
<ol> <li>Association, A.D., 6. Glycemic Targets. Diabetes Care, 2014. 38(Supplement_1): p. S33-S40.</li> <li>American Diabetes, A., Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2013. 37(Supplement_1): p. S81-S90.</li> <li>Morris, J.A., et al., An atlas of genetic influences on osteoporosis in humans and mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Staley, J.R. and B. Stephen, Softwar</li></ol>	472		data. Nature, 2018. 562(7726): p. 203-209.
<ul> <li>S33-S40.</li> <li>American Diabetes, A., Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2013. 37(Supplement_1): p. S81-S90.</li> <li>Morris, J.A., et al., An atlas of genetic influences on osteoporosis in humans and mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Conway, B.N., et al., Glycemic control and fracture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Statley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomiza</li></ul>	473	10.	Association, A.D., 6. Glycemic Targets. Diabetes Care, 2014. 38(Supplement_1): p.
<ol> <li>American Diabetes, A., Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2013. 37(Supplement_1): p. S81-S90.</li> <li>Morris, J.A., et al., An atlas of genetic influences on osteoporosis in humans and mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations (version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package thaf facilitates flexible and reproducible non-linear Mendelia</li></ol>	474		\$33-\$40.
<ul> <li>Care, 2013. 37(Supplement_1): p. S81-S90.</li> <li>Morris, J.A., et al., An atlas of genetic influences on osteoporosis in humans and mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2: peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of So</li></ul>	475	11.	American Diabetes, A., Diagnosis and Classification of Diabetes Mellitus. Diabetes
<ol> <li>Morris, J.A., et al., An atlas of genetic influences on osteoporosis in humans and mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations (version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Staley, J.R. and S. Burgess</li></ol>	476		Care, 2013. 37(Supplement_1): p. S81-S90.
<ul> <li>mice. Nature Genetics, 2019. 51(2): p. 258-266.</li> <li>Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Kaley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with</li></ul>	477	12.	Morris, J.A., et al., An atlas of genetic influences on osteoporosis in humans and
<ol> <li>Zhang, Z., Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemio</li></ol>	478		mice. Nature Genetics, 2019. 51(2): p. 258-266.
<ul> <li>(MICE) package. Ann Transl Med, 2016. 4(2): p. 30.</li> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations (version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK B</li></ul>	479	13.	Zhang, Z., Multiple imputation with multivariate imputation by chained equation
<ol> <li>Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019. 125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Burgess, S., et al., Guidelines for performing Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Parti</li></ol>	480		(MICE) package. Ann Transl Med, 2016. 4(2): p. 30.
<ol> <li>125: p. 194-199.</li> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichakul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomization using a doubly-ranked stratification Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographi</li></ol>	481	14.	Leanza, G., et al., Risk factors for fragility fractures in type 1 diabetes. Bone, 2019.
<ol> <li>Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnInr, an R package that facilitates flexible and reproducible non-linear Mendelian randomization using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 18(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotter</li></ol>	482		125: p. 194-199.
<ul> <li>diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.</li> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose</li></ul>	483	15.	Conway, B.N., et al., Glycemic control and fracture risk in elderly patients with
<ol> <li>Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study. Diabete</li></ol>	484		diabetes. Diabetes Research and Clinical Practice, 2016. 115: p. 47-53.
<ul> <li>Genetics, 2021. 53(6): p. 840-860.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Hadong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study. Diabetes Care, 2013, 36(6): p. 1619-1628.</li> </ul>	485	16.	Chen, J., et al., The trans-ancestral genomic architecture of glycemic traits. Nature
<ol> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations. Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study. Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ol>	486		Genetics, 2021. 53(6): p. 840-860.
<ul> <li>Wellcome Open Res, 2019. 4: p. 186.</li> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Coei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study. Diabetes Care, 2013, 36(6): p. 1619-1628.</li> </ul>	487	17.	Burgess, S., et al., Guidelines for performing Mendelian randomization investigations.
<ol> <li>Burgess, S., et al., Guidelines for performing Mendelian randomization investigations [version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study. Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ol>	488		Wellcome Open Res, 2019. 4: p. 186.
<ul> <li>[version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).</li> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>20. Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>21. Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>22. Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>23. Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>24. Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>25. Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>26. Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study. Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	489	18.	Burgess, S., et al., Guidelines for performing Mendelian randomization investigations
<ol> <li>Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with Multiple Instrumental Variables Using the Generalised Method of Moments. Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study. Diabetes Care, 2013, 36(6): p. 1619-1628.</li> </ol>	490		[version 2; peer review: 2 approved]. Wellcome Open Research, 2020. 4(186).
<ul> <li>Multiple Instrumental Variables Using the Generalised Method of Moments.</li> <li>Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>Diabetes Care, 2013, 36(6): p. 1619-1628.</li> </ul>	491	19.	Paul, S.C., M.P. Tom, and W. Frank, Estimating Structural Mean Models with
<ul> <li>Statistical Science, 2015. 30(1): p. 96-117.</li> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	492		Multiple Instrumental Variables Using the Generalised Method of Moments.
<ol> <li>Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. Bioinformatics, 2010. 26(22): p. 2867-2873.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study. Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ol>	493	• •	Statistical Science, 2015. 30(1): p. 96-117.
<ul> <li>studies. Bioinformatics, 2010. 26(22): p. 2867-2875.</li> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	494	20.	Manichaikul, A., et al., Robust relationship inference in genome-wide association
<ol> <li>Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5): p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>Diabetes Care, 2013, 36(6): p. 1619-1628.</li> </ol>	495	01	studies. Bioinformatics, 2010. 26(22): p. 2867-2873.
<ul> <li>Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5):</li> <li>p. 1497-1501.</li> <li>22. Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian</li> <li>randomization using a doubly-ranked stratification method. bioRxiv, 2022: p.</li> <li>2022.06.28.497930.</li> <li>23. Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package</li> <li>that facilitates flexible and reproducible non-linear Mendelian randomisation</li> <li>analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>24. Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear</li> <li>exposure-outcome relationship using instrumental variables with application to</li> <li>Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>508 25. Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics</li> <li>of UK Biobank Participants With Those of the General Population. American Journal</li> <li>of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>511 26. Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as</li> <li>Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	496	21.	Brion, MJ.A., K. Shakhbazov, and P.M. Visscher, Calculating statistical power in
<ul> <li>p. 1497-1501.</li> <li>Haodong, T., et al., Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. bioRxiv, 2022: p. 2022.06.28.497930.</li> <li>23. Amy, M.M. and B. Stephen, Software Application Profile: SUMnlmr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>24. Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>25. Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>26. Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>513</li> </ul>	49/		Mendelian randomization studies. International Journal of Epidemiology, 2013. 42(5):
<ul> <li>Haodong, I., et al., Relaxing parametric assumptions for non-linear Mendelian</li> <li>randomization using a doubly-ranked stratification method. bioRxiv, 2022: p.</li> <li>2022.06.28.497930.</li> <li>Amy, M.M. and B. Stephen, Software Application Profile: SUMnImr, an R package</li> <li>that facilitates flexible and reproducible non-linear Mendelian randomisation</li> <li>analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear</li> <li>exposure-outcome relationship using instrumental variables with application to</li> <li>Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics</li> <li>of UK Biobank Participants With Those of the General Population. American Journal</li> <li>of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as</li> <li>Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	498	22	p. 1497-1501.
<ul> <li>randomization using a doubly-ranked stratification method. bioRxiv, 2022; p. 2022.06.28.497930.</li> <li>23. Amy, M.M. and B. Stephen, Software Application Profile: SUMnlmr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021; p. 2021.12.10.21267623.</li> <li>24. Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>25. Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>26. Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>513</li> </ul>	499	22.	Haodong, I., et al., Relaxing parametric assumptions for non-linear Mendelian
<ul> <li>2022.06.28.497930.</li> <li>23. Amy, M.M. and B. Stephen, Software Application Profile: SUMnlmr, an R package that facilitates flexible and reproducible non-linear Mendelian randomisation analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>24. Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>25. Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>26. Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>213 Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	500		randomization using a doubly-ranked stratification method. blockxiv, 2022: p.
<ul> <li>Anny, M.M. and B. Stephen, Software Application Profile: SOMininr, an R package</li> <li>that facilitates flexible and reproducible non-linear Mendelian randomisation</li> <li>analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear</li> <li>exposure-outcome relationship using instrumental variables with application to</li> <li>Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics</li> <li>of UK Biobank Participants With Those of the General Population. American Journal</li> <li>of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as</li> <li>Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	501	22	2022.00.28.49/930.
<ul> <li>inat factifiates flexible and reproducible non-linear Mendelian randomisation</li> <li>analyses. medRxiv, 2021: p. 2021.12.10.21267623.</li> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear</li> <li>exposure-outcome relationship using instrumental variables with application to</li> <li>Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics</li> <li>of UK Biobank Participants With Those of the General Population. American Journal</li> <li>of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as</li> <li>Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	502	23.	Amy, M.M. and B. Stephen, Software Application Profile: SUMININF, and package
<ul> <li>Staley, J.R. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	505		unat facilitates flexible and reproducible non-linear Mendenan randomisation
<ul> <li>Staley, J.K. and S. Burgess, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	504	24	Stelay, J.D. and S. Durgass, Saminarametric methods for estimation of a nonlinear
<ul> <li>Solo exposure-outcome relationship using instrumental variables with application to</li> <li>Mendelian randomization. Genetic Epidemiology, 2017. 41(4): p. 341-352.</li> <li>Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics</li> <li>of UK Biobank Participants With Those of the General Population. American Journal</li> <li>of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as</li> <li>Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	505	24.	statey, J.K. and S. Burgess, Semiparametric methods for estimation of a nonlinear
<ul> <li>507 Interdenan randomization. Genetic Epidemiology, 2017. 41(4). p. 541-552.</li> <li>508 25. Fry, A., et al., Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>511 26. Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>513 Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	507		Mendelian randomization. Genetic Enidemiology 2017, 41(4): p. 341, 352
<ul> <li>508 25. Try, A., et al., Comparison of Sociodemographic and Readin-Related Characteristics</li> <li>509 of UK Biobank Participants With Those of the General Population. American Journal</li> <li>510 of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>511 26. Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as</li> <li>512 Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>513 Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	508	25	Ery A et al Comparison of Sociodemographic and Health-Related Characteristics
<ul> <li>507 of OK Brobank Fatterpants with Those of the General Fopulation. American Journal of Epidemiology, 2017. 186(9): p. 1026-1034.</li> <li>511 26. Oei, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>513 Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	500	23.	of UK Biobank Participants With Those of the General Population American Journal
<ul> <li>510 Ori, L., et al., High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as</li> <li>512 Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study.</li> <li>513 Diabetes Care, 2013. 36(6): p. 1619-1628.</li> </ul>	510		of Enidemiology 2017 186(9): p 1026-1034
512 Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study. 513 Diabetes Care, 2013. 36(6): p. 1619-1628.	510	26	Oei L. et al. High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as
513 Diabetes Care, 2013. 36(6): p. 1619-1628.	512	20.	Skeletal Complications of Inadequate Glucose Control. The Rotterdam Study
	513		Diabetes Care, 2013, 36(6): p. 1619-1628.

514	27.	Wang, B., et al., Unmasking Fracture Risk in Type 2 Diabetes: The Association of
515		Longitudinal Glycemic Hemoglobin Level and Medications. The Journal of Clinical
516		Endocrinology & Metabolism, 2022. 107(4): p. e1390-e1401.
517	28.	Li, CI., et al., Glycated Hemoglobin Level and Risk of Hip Fracture in Older People
518		with Type 2 Diabetes: A Competing Risk Analysis of Taiwan Diabetes Cohort Study.
519		Journal of Bone and Mineral Research, 2015. 30(7): p. 1338-1346.
520	29.	Hidayat, K., et al., Influence of glycemic control and hypoglycemia on the risk of
521		fracture in patients with diabetes mellitus: a systematic review and meta-analysis of
522		observational studies. Osteoporosis International, 2021. 32(9): p. 1693-1704.
523	30.	Altman, D.G., et al., Dangers of using "optimal" cutpoints in the evaluation of
524		prognostic factors. J Natl Cancer Inst, 1994. 86(11): p. 829-35.
525	31.	Douglas, G.A. and R. Patrick, The cost of dichotomising continuous variables. BMJ,
526		2006. 332(7549): p. 1080.
527	32.	Lee, R.H., et al., Glycemic Control and Insulin Treatment Alter Fracture Risk in
528		Older Men With Type 2 Diabetes Mellitus, J Bone Miner Res. 2019, 34(11); p. 2045-
529		2051.
530	33.	Karges, B., et al., Hemoglobin A1c Levels and Risk of Severe Hypoglycemia in
531		Children and Young Adults with Type 1 Diabetes from Germany and Austria: A
532		Trend Analysis in a Cohort of 37,539 Patients between 1995 and 2012. PLOS
533		Medicine 2014, 11(10): p. e1001742
534	34	Lee, A.K., et al., Severe Hypoglycemia and Risk of Falls in Type 2 Diabetes: The
535	011	Atherosclerosis Risk in Communities (ARIC) Study, Diabetes Care, 2020, 43(9): p.
536		2060-2065
537	35.	FORD, E.S., et al., Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c
538		among adults in the US*. Journal of Diabetes, 2011, 3(1): p. 67-73.
539	36.	English, E., et al., The effect of anaemia and abnormalities of erythrocyte indices on
540		HbA1c analysis: a systematic review. Diabetologia. 2015. 58(7): p. 1409-21.
541	37.	Vavanikunnel, J., et al., Association Between Glycemic Control and Risk of Fracture
542		in Diabetic Patients: A Nested Case-Control Study. The Journal of Clinical
543		Endocrinology & Metabolism, 2019, 104(5); p. 1645-1654.
544	38.	Schwartz, A.V., et al., Risk factors for lower bone mineral density in older adults with
545	200	type 1 diabetes: a cross-sectional study. The Lancet Diabetes & Endocrinology, 2022.
546		10(7): p. 509-518.
547	39.	DeFronzo, R.A., et al., Type 2 diabetes mellitus, Nature Reviews Disease Primers.
548	071	2015 1(1): p 15019
549	40	Katsarou A et al. Type 1 diabetes mellitus. Nature Reviews Disease Primers. 2017
550	10.	3(1): n 17016
551		5(1). p. 17010.
551		
552	Keywo	ords: Type 2 Diabetes, Type 1 Diabetes, Fractures, Bone mineral density, Glycemic
553	control, Mendelian randomization, HbA <sub>1c</sub> .	
554		
555	List of	abbreviations:

- 556 Genome-wide association study (GWAS), linkage disequilibrium (LD), type 2 diabetes (type
- 2 diabetes), polygenic risk scores (PRS), Mendelian randomization (MR), single nucleotide 557

- 558 polymorphism (SNP), body mass index (BMI), Bone mineral density (BMD), Dual X-ray
- absorptiometry (DXA).
- 560
- 561 Declarations
- 562 Not applicable.
- 563
- 564 Ethics approval and consent to participate
- 565 All studies were conducted in full accordance with the ethical principles outlined in the
- 566 Declaration of Helsinki, as revised in 2013, including adherence to protocols approved by
- their respective institutional ethics review committees and all participants provided written
- 568 informed consent.
- 569
- 570 Consent for publication
- 571 Not applicable.
- 572
- 573 Availability of data and materials

574 HbA1C summary statistics can be obtained from MAGIC consortium website 575 (https://magicinvestigators.org/downloads/). All data generated or analyzed during this study

- are included in this published article [and its supplementary information files].
- 577
- 578 Competing interests
- 579 The authors declare that they have no competing interests.
- 580
- 581 Funding

582 This project has received funding from the European Union's Horizon 2020 research and

583 innovation program under the MARIE SKŁODOWSKA-CURIE grant agreement no. 860898.

- 584 LO is funded by an Erasmus MC fellowship grant.
- 585

586 Authors' contributions

587 S.Ghatan, L.Oei, F.Rivadeneira, designed the study. S.Ghatan performed the analysis.

588 S.Ghatan, L.Oei, F.Rivadeneira, C.Medina-Gomez, F.Koromani, and K.trajanoska drafted the

589 manuscript. All authors contributed to the interpretation of data and critical revision of the

590 manuscript. All authors read and approved the final version of the manuscript.

- 591
- 592 Acknowledgments

John Kemp for providing assistance in coding and quality control of the estimated bone mineral density data. This research has been conducted using the UK Biobank Resource (accession ID: 67864). We express our gratitude to the study participants, whose participation made this work possible, and to the numerous colleagues who contributed to the collection, phenotypic characterization of clinical samples, as well as genotyping and analysis of GWAS data. S.Ghatan is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

600

601 Originality and Prior Publication

602 Parts of the results from this manuscript have been presented previously at the European

603 Calcified Tissue Society (ECTS) 2023 congress in Liverpool, England on 16<sup>th</sup> of April.